Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07333170

Acronym

P versicolor

Enrollment

Registered

2026-01-12

Start date

2026-02-28

Completion date

2026-11-30

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pityriasis Versicolor

Keywords

P versicolor

Brief summary

Pityriasis versicolor is a common superficial fungal infection caused by Malassezia species, characterized by hypo- or hyper-pigmented scaly patches on the skin. Topical antifungal agents are the mainstay of treatment. Ketoconazole has been widely used; however, newer agents such as luliconazole may offer improved efficacy and shorter treatment duration. This randomized controlled study aims to compare the efficacy and safety of topical luliconazole versus topical ketoconazole in patients with pityriasis versicolor. Treatment response will be assessed clinically and mycologically to determine comparative outcomes.

Detailed description

Pityriasis versicolor is a superficial fungal infection caused by Malassezia species and is commonly treated with topical antifungal agents. Ketoconazole is a conventional treatment, while luliconazole is a newer topical antifungal with potent activity against fungal organisms. This randomized controlled trial is designed to compare the clinical and mycological efficacy, safety, and tolerability of topical luliconazole versus topical ketoconazole in patients diagnosed with pityriasis versicolor. Eligible participants will be randomly allocated into two treatment groups and followed for treatment response and adverse effects. The findings of this study may help determine a more effective topical treatment option for pityriasis versicolor.

Interventions

DRUGLuliconazole Cream 1%

Ketoconazole is relatively hydrophilic with limited skin retention, whereas luliconazole is highly lipophilic, resulting in superior stratum corneum penetration, higher keratin binding, and prolonged antifungal activity.

DRUGTopical ketoconazole 2% cream

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Masking description

This is an open-label study; no participants, care providers, investigators, or outcome assessors are masked.

Intervention model description

Participants will be randomly assigned into two parallel groups. One group will receive topical luliconazole, while the other group will receive topical ketoconazole for the treatment of pityriasis versicolor. Clinical and mycological outcomes will be compared between the two groups.

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* All patients diagnosed with pityriasis versicolor.

Exclusion criteria

* Immunocompromised patients

Design outcomes

Primary

Measure	Time frame	Description
Clinical and mycological cure rate in pityriasis versicolor.	4 weeks	Proportion of participants achieving both clinical and mycological cure.
Clinical and mycological cure	4 weeks after completion of treatment	Proportion of participants achieving both clinical and mycological cure

Contacts

Primary ContactSana Rafique, MBBS

sanafmdc@gmail.com+923355956563

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026